

ADVANCED
OVARIAN CANCER:
OPTIMAL THERAPY

VENUE:

All sessions will take place
at the Palau de la Música
Paseo de la Alameda, 30
46023 Valencia, Spain

LANGUAGE:

The official language of the
Symposium is English.
Simultaneous translation
into Spanish will be provided.

DIRECTORS:

A. POVEDA
(Valencia, Spain)

J.B. VERMORKEN
(Antwerp, Belgium)

Under the auspices of:
ESMO, SEOM, GEICO

Organized by:
GEICO (Grupo Español de
Investigación en Cáncer de Ovario)

**CONFERENCE
SECRETARIAT:**


Doctaforum,
Congresos y Reuniones Científicas
Avda. Campo de Calatrava, 17, 4-PB-1,
28034 Madrid, Spain
Tel.: +34 91 372 0203
Fax: +34 91 735 0454
E-mail: geico_symp@doctaforum.com

ORGANIZED BY:



GEICO
(GRUPO ESPAÑOL DE
INVESTIGACIÓN EN
CÁNCER DE OVARIO)

UNDER THE AUSPICES OF:
ESMO, SEOM, GEICO



5TH INTERNATIONAL
SYMPOSIUM

ADVANCED
OVARIAN CANCER:
OPTIMAL THERAPY

FEBRUARY 25th, 2005
PALAU DE LA MÚSICA
VALENCIA, SPAIN

PROGRAM

08:30
WELCOME

09:00
OVARIAN CANCER
IN THE PROTEOMIC ARENA
Elise C. Kohn (Bethesda, USA)

1ST SESSION: MISCELLANEOUS

Chairmen: Jacobus Pfisterer (Kiel, Germany)
César Mendiola (Madrid, Spain)

09:30 - 10:00
NEW TUMOR MARKERS:
CA125 AND BEYOND
Robert Bast Jr. (Houston, USA)

ROLE OF CONSERVATIVE
SURGERY IN OVARIAN CANCER:

10:00 - 10:30
The US Experience. Bradley J. Monk (Orange, USA)

10:30 - 11:00
The European Experience. Nicoletta Colombo (Milan, Italy)

11:00
COFFEE BREAK

2ND SESSION: FIRST-LINE THERAPIES

Chairmen: Antonio Casado (Madrid, Spain)
Elizabeth Eisenhauer (Kingston, Canada)

11:30 - 11:50
STANDARD TREATMENT IN
ADVANCED OVARIAN CANCER
IN 2005: THE STATE OF THE ART
Michael A. Bookman (Philadelphia, USA)

FINAL RESULTS OF GCIG
RANDOMIZED STUDIES:

11:50 - 12:10
The TEC vs. TC AGO-GINECO Study
Eric Pujade (Paris, France)

12:10 - 12:30
The TEC vs. TC NSGO-EORTC-NCIC-GEICO Study
Gunnar Kristensen (Oslo, Norway)

12:30 - 12:50
The GCT vs. TC (Ovar-9) Study
Jacobus Pfisterer (Kiel, Germany)

WHAT IS THE ROLE
OF DOSE-DENSE THERAPY:

12:50 - 13:10
Pros. Maria EL van den Burg (Rotterdam, The Netherlands)

13:10 - 13:30
Cons. Paul Vasey (Brisbane, Australia)

14:00
LUNCH

3RD SESSION: TREATMENT OF RECURRENT DISEASE

Chairmen: Andrés Cervantes (Valencia, Spain)
David Spriggs (New York, USA)

15:00 - 15:30
RANDOMIZED TRIALS
OF SINGLE AGENTS
Cristiana Sessa (Bellinzona, Switzerland)

15:30 - 16:00
RANDOMIZED TRIALS OF SINGLE VS.
COMBINATION CHEMOTHERAPY
Antonio González (Madrid, Spain)

16:00 - 16:30
IS THERE STILL A ROLE
FOR HORMONAL THERAPY?
Michael A. Bookman (Philadelphia, USA)

16:30 - 17:00
ROLE OF SURGERY IN
RECURRENT DISEASE
Jacobus Pfisterer (Kiel, Germany)

17:00
COFFEE BREAK

4TH SESSION: NEW THERAPEUTIC APPROACHES

Chairmen: Jan B. Vermorken (Antwerp, Belgium),
Paul Vasey (Brisbane, Australia)

17:30 - 18:10
MOLECULAR PROGNOSTIC FACTORS
Elisabeth de Vries (Gröningen, The Netherlands)

18:10 - 18:50
NEW TARGETED THERAPIES
David Spriggs (New York, USA)

18:50 - 19:30
TRIAL DESIGN FOR TESTING
NEW THERAPIES
Elizabeth Eisenhauer (Kingston, Canada)

19:30 - 19:40
REMARKS AND CONCLUSIONS
Andrés Poveda (Valencia, Spain)



ADVANCED
OVARIAN CANCER:
OPTIMAL THERAPY